Extramedullary relapse after allogeneic bone marrow transplantation plus buffy-coat in two high risk patients

Haematologica

Volumn 81, Issue 2, 1996, Pages 182-185

  Salutari, Prassede ^a   Sica, Simona ^a   Micciulli, Giulia ^a   Rutella, Sergio ^a   Di Mario, Antonella ^a   Leone, Giuseppe ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Allogeneic BMT; Donor leukocyte infusion; Extramedullary leukemia relapse

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA REMISSION; MALE; T CELL LEUKEMIA; TREATMENT OUTCOME;

ADULT; BONE MARROW TRANSPLANTATION; FEMALE; HEMATOPOIESIS, EXTRAMEDULLARY; HUMANS; LEUKEMIA, T-CELL, CHRONIC; LEUKOCYTE COUNT; LYMPHOMA, B-CELL; MALE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030326549     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft versus host disease on relapse and survival after bone marrow transplantation from HLA identical siblings as. treatment of acute and chronic leukemia. Blood 1987; 73:1720-8.
2. Falkenburg JHF, Willemze R. Donor cell mediated antileukemic reactivity after allogeneic bone marrow transplantation. Curr Opinion Hematol 1993; 6:228-33.
3. Van Loken E, de Gast B,Goulmy E. In vitro separation of host specific graft versus host and graft versus leukemia cytotoxic T cell activities. Bone Marrow Transpl 1992; 10:181-3.
4. Kolb HJ, Mittermuller J, Clemm C,et al. Donor leukocyte transfusion for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2642-5.
5. Porter DL, Roth M, Mc Garigle C, Ferrara JLM, Antin JH. Induction of graft versus host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 13:100-6.
6. Goldberg SL, Mangan KF, Klumpp TR, Cropper TM, Schnall SF, MacDonald JS. Lack of graft versus leukemia effect in an immunologically privileged sanctuary site. Bone Marrow Transpl 1994; 14:173-81.
7. Truitt RL, LeFever AV, Shih CCY, Jeske JM, Martin TM. Graft vs. host disease: immunology, pathophysiology. New York: Marcel Dekker, 1990:177-204.
8. Goldman IM, Gale RP, Horowitz MM. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108:806-14.
9. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusion of donor leukocytes to treat Epstein Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330:1185-91.
10. Hauch M, Cazzola MV, Small T, et al. Antileukemic potential of IL2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 75:2250-62.
11. Naparstek E, Or R, Nagler A, et al. T-cell depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89: 506-15.
12. Viard F, Bilhou-Naberac C, Marit G, et al. Infrequent sites of extramedullary relapse after allogeneic bone marrow transplantation. Nouv Rev Fr Hematol 1995; 37:153-7.